Development Of A Collaborative European Pharmacoepidemiologic Post-Authorization Safety Study (Pass) Programme Examining Rivaroxaban Use In Routine Clinical Practice

Affiliations

• ¹ Bayer Pharma AG, Berlin, Germany.
• ² Ceife - Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain.
• ³ Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
• ⁴ Pharmo Institute for Drug Outcomes Research, Utrecht, The Netherlands.
• ⁵ Drug Safety Research Unit, Southampton, UK.
• ⁶ Friberg Research AB, Stockholm, Sweden.
• ⁷ Oxford PharmaGenesis™ Ltd, Oxford, UK.
• ⁸ Uppsala University, Uppsala, Sweden.